Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has released its 2024 Sustainability Report highlighting significant environmental and social achievements. The company achieved a 30% reduction in greenhouse gas emissions intensity since 2020 and a 28% reduction in water consumption intensity since 2019.
Key highlights include:
- 54% of STEM positions held by female employees
- Nearly 10,000 employee volunteer hours in local communities
- Support for 21 integrated rare disease projects
- 90% of Kaizen projects achieved ESG benefits
- Green CRDMO solutions achieving up to 80% reduction in product carbon footprint
The company received multiple sustainability recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices. Through its CRDMO+ strategy focusing on Client+, Global+, Innovation+, and Agility+, WuXi Biologics continues to align with UN Sustainable Development Goals while delivering value to stakeholders.
WuXi Biologics, un'organizzazione globale di Ricerca, Sviluppo e Produzione a contratto (CRDMO), ha pubblicato il suo Rapporto sulla Sostenibilità 2024, evidenziando importanti risultati ambientali e sociali. L'azienda ha ridotto l'intensità delle emissioni di gas serra del 30% dal 2020 e il consumo d'acqua del 28% dal 2019.
Punti salienti:
- Il 54% delle posizioni STEM è occupato da donne
- Quasi 10.000 ore di volontariato dei dipendenti nelle comunità locali
- Sostegno a 21 progetti integrati sulle malattie rare
- Il 90% dei progetti Kaizen ha portato benefici ESG
- Soluzioni CRDMO ecologiche con riduzione fino all'80% dell'impronta di carbonio del prodotto
L'azienda ha ricevuto numerosi riconoscimenti per la sostenibilità, tra cui la valutazione MSCI AAA, la Medaglia Platinum EcoVadis e l'inclusione negli Indici di Sostenibilità Dow Jones. Attraverso la strategia CRDMO+ focalizzata su Client+, Global+, Innovation+ e Agility+, WuXi Biologics continua ad allinearsi agli Obiettivi di Sviluppo Sostenibile delle Nazioni Unite, offrendo valore agli stakeholder.
WuXi Biologics, una organización global de Investigación, Desarrollo y Manufactura por contrato (CRDMO), ha publicado su Informe de Sostenibilidad 2024 destacando importantes logros ambientales y sociales. La compañía logró una reducción del 30% en la intensidad de emisiones de gases de efecto invernadero desde 2020 y una reducción del 28% en la intensidad del consumo de agua desde 2019.
Puntos clave:
- El 54% de los puestos STEM están ocupados por mujeres
- Casi 10,000 horas de voluntariado de empleados en comunidades locales
- Apoyo a 21 proyectos integrados de enfermedades raras
- El 90% de los proyectos Kaizen lograron beneficios ESG
- Soluciones CRDMO verdes que alcanzan hasta un 80% de reducción en la huella de carbono del producto
La empresa recibió múltiples reconocimientos de sostenibilidad, incluyendo la calificación MSCI AAA, la Medalla Platino de EcoVadis y la inclusión en los Índices de Sostenibilidad Dow Jones. A través de su estrategia CRDMO+ enfocada en Client+, Global+, Innovation+ y Agility+, WuXi Biologics continúa alineándose con los Objetivos de Desarrollo Sostenible de la ONU mientras genera valor para sus grupos de interés.
WuXi Biologics는 글로벌 계약 연구, 개발 및 제조 조직(CRDMO)으로서 2024년 지속 가능성 보고서를 발표하며 중요한 환경 및 사회적 성과를 강조했습니다. 회사는 2020년 이후 온실가스 배출 강도를 30% 줄였고, 2019년 이후 물 사용 강도를 28% 감소시켰습니다.
주요 내용은 다음과 같습니다:
- STEM 직위의 54%를 여성 직원이 차지
- 지역 사회에서 약 10,000시간의 직원 자원봉사
- 21개의 통합 희귀질환 프로젝트 지원
- Kaizen 프로젝트의 90%가 ESG 혜택 달성
- 제품 탄소 발자국을 최대 80%까지 줄이는 친환경 CRDMO 솔루션
회사는 MSCI AAA 등급, EcoVadis 플래티넘 메달, 다우존스 지속 가능성 지수 포함 등 다수의 지속 가능성 인증을 받았습니다. Client+, Global+, Innovation+, Agility+에 중점을 둔 CRDMO+ 전략을 통해 WuXi Biologics는 UN 지속 가능 개발 목표와 계속 연계하며 이해관계자에게 가치를 제공합니다.
WuXi Biologics, une organisation mondiale de recherche, développement et fabrication sous contrat (CRDMO), a publié son rapport de durabilité 2024 mettant en avant des réalisations environnementales et sociales majeures. L'entreprise a réduit l'intensité des émissions de gaz à effet de serre de 30 % depuis 2020 et l'intensité de la consommation d'eau de 28 % depuis 2019.
Points clés :
- 54 % des postes STEM occupés par des femmes
- Près de 10 000 heures de bénévolat des employés dans les communautés locales
- Soutien à 21 projets intégrés de maladies rares
- 90 % des projets Kaizen ont généré des bénéfices ESG
- Solutions CRDMO écologiques réduisant jusqu'à 80 % l'empreinte carbone des produits
L'entreprise a reçu plusieurs distinctions en matière de durabilité, notamment la note MSCI AAA, la médaille Platine EcoVadis et son inclusion dans les indices de durabilité Dow Jones. Grâce à sa stratégie CRDMO+ axée sur Client+, Global+, Innovation+ et Agility+, WuXi Biologics continue de s'aligner sur les Objectifs de Développement Durable de l'ONU tout en apportant de la valeur à ses parties prenantes.
WuXi Biologics, ein globales Contract Research, Development und Manufacturing Organization (CRDMO), hat seinen Nachhaltigkeitsbericht 2024 veröffentlicht, der bedeutende Umwelt- und Sozialleistungen hervorhebt. Das Unternehmen erreichte eine Reduzierung der Treibhausgasemissionsintensität um 30 % seit 2020 und eine Verringerung der Wasserverbrauchsintensität um 28 % seit 2019.
Wesentliche Highlights:
- 54 % der STEM-Positionen sind von weiblichen Mitarbeitenden besetzt
- Fast 10.000 Stunden ehrenamtliche Mitarbeit in lokalen Gemeinschaften
- Unterstützung von 21 integrierten Projekten zu seltenen Krankheiten
- 90 % der Kaizen-Projekte erzielten ESG-Vorteile
- Grüne CRDMO-Lösungen mit bis zu 80 % Reduktion des CO2-Fußabdrucks von Produkten
Das Unternehmen erhielt mehrere Auszeichnungen für Nachhaltigkeit, darunter die MSCI AAA-Bewertung, die EcoVadis Platin-Medaille und die Aufnahme in die Dow Jones Sustainability Indices. Mit seiner CRDMO+-Strategie, die sich auf Client+, Global+, Innovation+ und Agility+ konzentriert, bleibt WuXi Biologics im Einklang mit den UN-Nachhaltigkeitszielen und schafft gleichzeitig Mehrwert für die Stakeholder.
- Achieved 30% reduction in GHG emissions intensity from 2020 baseline, demonstrating operational efficiency
- Received top-tier ESG ratings: MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in Dow Jones Sustainability Indices
- Supporting 21 integrated rare disease projects, expanding market presence in specialty therapeutics
- Successfully implementing 'Follow and Win the Molecule' strategy with proprietary technology platforms
- 90% of Kaizen projects achieved ESG benefits, indicating strong operational optimization
- Diverse global workforce with employees from 53 nationalities, supporting international market expansion
- None.
- Contributing to United Nations Sustainable Development Goals
- Enhancing transparency and effectiveness for corporate governance
- Empowering employees and delivering positive impact to communities
- Accelerating actions for tackling climate change and promoting environmental stewardship
- Providing Green CRDMO solutions to empower global clients on their sustainability journeys
Unleashing the power of its unique CRDMO business model, technology strength and operational excellence, WuXi Biologics has successfully continued to execute its "Follow and Win the Molecule" strategies, while maintaining vigorous momentum and making notable sustainability achievements in 2024.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "At WuXi Biologics, we believe that long-term business success is inseparable from our responsibility to people, society and the planet. With sustainability as the enduring cornerstone of business growth, we keep empowering our global clients with advanced end-to-end Green CRDMO solutions, and driving environmental transformation of the biopharmaceutical industry."
Enhancing Governance Transparency and Effectiveness
Guided by a comprehensive sustainability strategy, the company has established strong corporate governance mechanisms and processes. It sets goals according to a science-based and measurable ESG target matrix — aligned with the United Nations Sustainable Development Goals (UN SDGs) — and subsequently develops refined roadmaps, and tracks progress for continuous improvement.
WuXi Biologics is fully committed to maintaining transparent dialogues and building strong connections with all stakeholders. As an active participant of the Pharmaceutical Supply Chain Initiative (PSCI), it firmly upholds PSCI principles in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.
Empowering People and Communities
The company takes great pride in all the accomplishments made by its employees, who are highly dedicated and experienced professionals, representing 53 nationalities with diverse backgrounds. It actively supports the career development of women in the areas of Science, Technology, Engineering and Mathematics (STEM), with
WuXi Biologics prioritizes community engagement as a catalyst for measurable social value. In 2024, nearly 10,000 employee volunteer hours were logged in local communities around the world. Leveraging company's core competencies to drive the breakthrough treatments that improve patients' outcomes is one of its three pillars of corporate social responsibilities. An important part of that lies in the collaboration with global clients to bring novel treatments to patients with rare diseases. As of 2024, WuXi Biologics is actively supporting 21 integrated rare disease projects.
Accelerating actions for tackling climate change and promoting environmental stewardship
Ensuring the planet's resilience begins with the choices that are made today. WuXi Biologics recognizes that protecting the planet is not just a responsibility but a necessity for future generations. The company has long been dedicated to the perpetuation of good environmental stewardship regarding climate change, resource efficiency, circularity, ecosystem protection, and green innovation. In 2024, the company achieved a
As part of its drive to advance an eco-friendly transition for the biopharmaceutical industry, WuXi Biologics has actively integrated green concepts into multiple innovative and proprietary technology platforms — including WuXiBody™, WuXiUP™, WuXiUI™, and WuXiDARx™ — and employs environmentally friendly single-use technology (SUT), providing global clients with end-to-end green solutions for biologics research, development and manufacturing. The Green CRDMO solution — with an up to
To drive continuous improvement for operational excellence, the WuXi Biologics Business System (WBS) utilizes a Lean Management philosophy and integrates it with ESG initiatives. Over
Global Impact, Shared Future
WuXi Biologics' steadfastness in promoting sustainable development has earned widespread recognition. The company was granted an MSCI AAA Rating, awarded an EcoVadis Platinum Medal, listed in the Dow Jones Sustainability Indices (DJSI), named to CDP Water Security "A list" and awarded A- CDP Climate Change leadership-level score for two consecutive years; named as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series, listed in the Hang Seng ESG 50 Index, and rated as Prime by ISS ESG Corporate Rating.
Dr. Chris Chen commented, "Looking ahead to 2025 and beyond, we will continue to have sustainability serve as the cornerstone of our innovation, operations, and growth. By implementation of our new CRDMO+ strategy—with key pillars of Client+, Global+, Innovation+, and Agility+ — WuXi Biologics will contribute to accelerating the advancement of the United Nations Sustainable Development Goals and enable global clients to bring life-changing treatments to patients worldwide, delivering value and shared success to all of our stakeholders for a healthier future."
Download 2024 Sustainability Report
https://www.wuxibiologics.com/sustainability/
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/driving-impact-through-responsibility-wuxi-biologics-releases-2024-sustainability-report-302441134.html
SOURCE WuXi Biologics
FAQ
What sustainability goals did WuXi Biologics (WXXWY) achieve in 2024?
How is WuXi Biologics (WXXWY) addressing environmental sustainability in biotech manufacturing?
What ESG ratings and recognitions did WuXi Biologics (WXXWY) receive in 2024?
How does WuXi Biologics (WXXWY) support diversity and inclusion in STEM?
What is WuXi Biologics' (WXXWY) CRDMO+ strategy for 2025?
